tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2012 May 9. [Epub ahead of print]
Higher titer and avidity of non-neutralizing antibodies against influenza vaccine antigen are associated with severe influenza.
To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, Ng JC, Chan JF, Chan KH, Yuen KY.
Source
Research Centre of Infection and Immunology.
Abstract
The importance of neutralizing antibody in protection against influenza virus is well established but the role of early antibody response during the initial stage of infection affecting disease severity is unknown. The 2009 pandemic influenza provided a unique opportunity because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody response of 52 patients with severe or mild disease in their serum collected at admission. Microneutralization assay (MN) was used to detect neutralizing antibody. We have also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and non-neutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titer was not significantly different between the two groups (p=0.764), the ELISA titer and the ELISA:MN titer ratio were significantly higher in patients with severe disease than those with mild disease (p=0.004 and p=0.011, respectively). This finding suggested that in patients with severe disease, a higher proportion of their serum antibodies are the antibody with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than those with mild disease (p<0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titer than those who did not require PPV (p<0.05). Multivariate analysis showed that ELISA titer and antibody avidity were independently associated with severe disease. Higher titer of non-neutralizing antibody with higher avidity present at the early stage of influenza infection may be associated with worse clinical severity and poorer outcome.
PMID:
22573737
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22573737
Higher titer and avidity of non-neutralizing antibodies against influenza vaccine antigen are associated with severe influenza.
To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, Ng JC, Chan JF, Chan KH, Yuen KY.
Source
Research Centre of Infection and Immunology.
Abstract
The importance of neutralizing antibody in protection against influenza virus is well established but the role of early antibody response during the initial stage of infection affecting disease severity is unknown. The 2009 pandemic influenza provided a unique opportunity because most patients lacked preexisting neutralizing antibody. In this study, we compared the antibody response of 52 patients with severe or mild disease in their serum collected at admission. Microneutralization assay (MN) was used to detect neutralizing antibody. We have also developed an enzyme-linked immunosorbent assay (ELISA) which detects both neutralizing and non-neutralizing antibodies against viral antigens from a split-virion inactivated monovalent influenza virus vaccine. While the MN titer was not significantly different between the two groups (p=0.764), the ELISA titer and the ELISA:MN titer ratio were significantly higher in patients with severe disease than those with mild disease (p=0.004 and p=0.011, respectively). This finding suggested that in patients with severe disease, a higher proportion of their serum antibodies are the antibody with no detectable neutralizing activity. The antibody avidity was also significantly higher in patients with severe disease than those with mild disease (p<0.05). Among patients with severe disease, those who required positive pressure ventilation (PPV) had significantly higher ELISA titer than those who did not require PPV (p<0.05). Multivariate analysis showed that ELISA titer and antibody avidity were independently associated with severe disease. Higher titer of non-neutralizing antibody with higher avidity present at the early stage of influenza infection may be associated with worse clinical severity and poorer outcome.
PMID:
22573737
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22573737